IBD

Cabot Corporation Launches EVOLVE™ Sustainable Solutions Technology Platform Focused on Advancing Sustainable Reinforcing Carbons

Retrieved on: 
Tuesday, March 21, 2023
Automotive Manufacturing, Manufacturing, Batteries, Technology, Chemicals, Plastics, Carbon, International Sustainability Alliance, Newsweek, ASTM, IBD, Cabot Corporation, Platinum, Table tennis rubber, GHG, Multimedia, ISCC, N550, NYSE, Plant, Cabot, Corporation, Pyrolysis, EVOLVE, CO2, Renewable energy, Engineered wood, Recycling, Tire manufacturing

Cabot Corporation (NYSE: CBT) today announced the launch of EVOLVE™ Sustainable Solutions, a new technology platform for advancing sustainable reinforcing carbons.

Key Points: 
  • Cabot Corporation (NYSE: CBT) today announced the launch of EVOLVE™ Sustainable Solutions, a new technology platform for advancing sustainable reinforcing carbons.
  • View the full release here: https://www.businesswire.com/news/home/20230321005243/en/
    Increased environmental pressures are driving greater demand for sustainable reinforcing carbon solutions that support a circular, sustainable economy as well as decrease GHG emissions.
  • The introduction of EVOLVE Sustainable Solutions is an important step in Cabot’s journey to develop new ways to create materials that improve daily life and enable a more sustainable future.
  • Cabot has launched two new products powered by EVOLVE Sustainable Solutions under the recovered category, VULCAN® 7H-C circular reinforcing carbon and STERLING® SO-RC110 circular reinforcing carbon that will leverage an ISCC PLUS certified mass balance approach.

Comera Life Sciences Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

Retrieved on: 
Thursday, March 16, 2023
Research, SQ, Conference, Drug development, Quality of life, Inflammatory bowel disease, IBD, Caffeine, Ulcerative colitis, Half-life, Partnership, Biotechnology, Mab, Ipilimumab, Science, Patient, Toxicity, Animal, Regeneron Pharmaceuticals, Excipient, Safety, CMRA, IV, Pharmaceutical industry, Management, Cryptocurrency, Airline

WOBURN, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

Key Points: 
  • “During 2022, Comera generated significant momentum, strengthening of the Company’s capabilities, team, proprietary pipeline, and executing pharmaceutical partnerships to drive value for Comera shareholders and our partners.
  • These accomplishments have positioned Comera to achieve substantial progress across our business,” said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera.
  • Comera had $2.0 million in cash, cash equivalents, and restricted cash at December 31, 2022.
  • R&D expenses totaled $1.7 million for the year-ended December 31, 2022, compared to $1.8 million for the same period in 2021.

Tonghai Financial Announces Appointment of Ambrose Lam as Co-Chairman of China Tonghai Capital (Holdings) Limited

Retrieved on: 
Tuesday, March 14, 2023
IBD, Institute of Chartered Accountants of Scotland, Certified Public Accountant, Newcastle University, Knowledge, Growth, Ambrose, Hong Kong Institute of Certified Public Accountants, Holding, Newcastle upon Tyne, University, Bank

HONG KONG, Mar 14, 2023 - (ACN Newswire) - China Tonghai International Financial Limited (Stock Code: 00952.HK) is pleased to announce that Mr. Ambrose Lam as the Co-Chairman of its wholly owned subsidiary China Tonghai Capital (Holdings) Limited (Tonghai Capital), with effect from January 15, 2023.

Key Points: 
  • HONG KONG, Mar 14, 2023 - (ACN Newswire) - China Tonghai International Financial Limited (Stock Code: 00952.HK) is pleased to announce that Mr. Ambrose Lam as the Co-Chairman of its wholly owned subsidiary China Tonghai Capital (Holdings) Limited (Tonghai Capital), with effect from January 15, 2023.
  • In the new role of Co-Chairman of China Tonghai Capital, Ambrose will support the Group in encompassing all of Tonghai Capital's businesses including IBD, Debt Capital Markets and Capital Market Solutions, providing our clients with a comprehensive service to facilitate their different financing demands.
  • Ambrose is joining Tonghai Financial with impressive track records, adding a wealth of experience at this important juncture.
  • He is expected to drive our corporate finance business into the future, with the clear objective to position Tonghai Financial for a successful future and realize its full potential.

Oral Clinical Nutrition Market Size, Share & Trends Analysis Report By Stage, By Indication, By Sales Channel, By Region And Segment Forecasts, 2023 - 2030

Retrieved on: 
Tuesday, March 14, 2023
Nutrient deficiency, Protein, Conditional sentence, Alzheimer's disease, Government, Electrolyte, Genome Canada, Somatic symptom disorder, Incidence, Clinical, R, Prevalence, Immunity, Hypertension, Ottawa University, White House conference, Vitamin, Cancer, Filament, Abbott, Growth, COVID-19, Dicarboxylic acid, CIHR, Research, CHEO, Sale, Obesity, Oral, Dysphagia, Mineral, Conference, Malnutrition, Food, Vitamin D, IBD, USD, Yogurt, Dietary supplement, Hospital, Pediatrics, Health, Hunger

They also have a wide range of applications in the treatment of chronic diseases such as cancer, neurological conditions and gastrointestinal disorders.

Key Points: 
  • They also have a wide range of applications in the treatment of chronic diseases such as cancer, neurological conditions and gastrointestinal disorders.
  • Such initiative has led to the development of more advanced and effective oral clinical nutrition supplements, which has increased their adoption and growth in the market.
  • Further, the COVID-19 pandemic has had a positive impact on the oral clinical nutrition market.The demand for oral clinical nutrition supplements has increased catering to the issues faced due to malnutrition.
  • Cancer care segment held the largest share in 2022 owing to its rising prevalence and hospital admissions for cancer treatment.

Health Catalyst, GIQuIC Team Up to Power the Nation's Only Gastroenterology-Focused Clinical Registry

Retrieved on: 
Tuesday, March 14, 2023
ERCP, American College of Gastroenterology, EUS, Colonoscopy, Patient, ASGE, MMM, American College, American Society for Gastrointestinal Endoscopy, ACG, FACG, Data management, EBT, Gastrointestinal Endoscopy, Data collection, Society, EGD, Inflammatory bowel disease, HCAT, SALT, IBD, Partnership, Nursing, Medical device, MD

As noted in Health Catalyst's Q4 2022 earnings call announcement, GIQuiC which offers the only national gastroenterology-focused clinical registry, will utilize ARMUS by Health Catalyst's HYBRID Clinical Registry and Reporting solution to advance the extraction process, including a streamlined user experience, enhanced data capture process, and improved reporting.

Key Points: 
  • As noted in Health Catalyst's Q4 2022 earnings call announcement, GIQuiC which offers the only national gastroenterology-focused clinical registry, will utilize ARMUS by Health Catalyst's HYBRID Clinical Registry and Reporting solution to advance the extraction process, including a streamlined user experience, enhanced data capture process, and improved reporting.
  • "This collaboration will enhance the service we already provide to our registry participants by allowing GIQuIC to leverage the depth and breadth of offerings and prior experience and success Health Catalyst has with respect to registry services and healthcare analytics.
  • "Data abstraction and registry reporting are critical functions of healthcare organizations, and we are delighted GIQuIC has selected Health Catalyst to power this important work," said Dan Burton, CEO of Health Catalyst.
  • "We look forward to an enduring partnership with the GIQuIC team and registry participants."

Lateral Investment Management Expands Distribution Team to Focus on Retail Channel

Retrieved on: 
Tuesday, March 14, 2023
Retail, Professional Services, Other Retail, Finance, Investment, United Nations Convention on Contracts for the International Sale of Goods, Tic, Van Kampen Investments, Security, Invest Financial Corporation, Invesco, Registered investment adviser, Real estate investment trust, Region, Certified Financial Planner, IBD, GARP, Securities Industry and Financial Markets Association, Legendary, RIA, Certification, Wholesaling, FINRA, National accounts, Broker-dealer, Financial adviser

All three will be working closely with the Registered Investment Advisor and Broker-Dealer channel as part of Lateral’s plans to extend distribution of its private equity products to qualified clients in the retail channel.

Key Points: 
  • All three will be working closely with the Registered Investment Advisor and Broker-Dealer channel as part of Lateral’s plans to extend distribution of its private equity products to qualified clients in the retail channel.
  • Angela has worked with REITS, limited partnerships, Reg D offerings, private and public securities, and traditional investment assets.
  • Ken Johnson, Regional Vice President of Sales, focuses on fundraising as a wholesaler in the IBD channel.
  • Ken earned a Certified Financial Risk Manager designation through GARP in 2006 in his role as Portfolio/Risk Manager for $2 billion AUM traditional and non-traditional investment strategies.

Assertio Appoints Dr. Howard Franklin as Senior Vice President, Medical

Retrieved on: 
Monday, March 6, 2023
Odyssey, La Salle University, Salix Pharmaceuticals, Acquisition, Business administration, Patient, Massachusetts General Hospital, Lehigh University, Long Island, IBD, Harvard Medical School, Master of Business Administration, Spectrum, Hospital, Long Island Jewish Medical Center, Sequah Medicine Company, General surgery, ASRT, Nursing, Pharmaceutical industry, MD, Assertio Therapeutics, Medicine

LAKE FOREST, Ill., March 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced the appointment of Howard J. Franklin, MD, as Senior Vice President, Medical.

Key Points: 
  • LAKE FOREST, Ill., March 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced the appointment of Howard J. Franklin, MD, as Senior Vice President, Medical.
  • “I am excited to join the team and create a best-in-class clinical development and medical affairs program that builds on the legacy of successful commercial innovation established here at Assertio,” said Dr. Franklin.
  • He previously held senior roles at Icon Bioscience, Oceana Therapeutics, The Medicines Company, Esprit Pharmaceuticals and Odyssey Pharmaceuticals.
  • He completed his medical residency in general surgery at Long Island Jewish Medical Center, followed by a fellowship in lapro-endoscopy and minimally invasive surgery at Massachusetts General Hospital, Harvard Medical School.

IBD/TIPP Economic Optimism Continues to Rise in March

Retrieved on: 
Tuesday, March 7, 2023
Data Analytics, Professional Services, Business, Finance, Optimism, Quality of life, Pessimism, Reading, Index, Favored placement, The Conference Board, Government, University, Conference, IBD, Personal, St. Louis Fed Financial Stress Index, Economic Outlook, Cryptocurrency, Financial adviser

The IBD/TIPP Economic Optimism Index , a leading national poll on consumer confidence, increased for the second consecutive month.

Key Points: 
  • The IBD/TIPP Economic Optimism Index , a leading national poll on consumer confidence, increased for the second consecutive month.
  • The IBD/TIPP Economic Optimism Index has established a strong track record of foreshadowing the confidence indicators issued later each month by the University of Michigan and The Conference Board.
  • While the numbers aren’t yet stable, March is the second consecutive month where we’re seeing improvements.”
    The flagship IBD/TIPP Economic Optimism Index has three key components.
  • Confidence in Federal Economic Policies, a proprietary IBD/TIPP measure of views on how government economic policies are working, increased from 43.1 to 44.2, a 2.6% change.

Enthera Pharmaceuticals Initiates Phase 1 Clinical Trial with Lead Candidate Ent001

Retrieved on: 
Tuesday, March 7, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Clinical Trials, Pancreas, Cell death, Clinical trial, TMEM219, Inflammatory bowel disease, FIH, T1D, Mab, SAD, Patient, Pharmacokinetics, Apoptosis, Volunteering, IBD, IGFBP3, Inflammation, Safety, Medication, Pharmaceutical industry

Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions, today announces the start of a Phase 1 first-in-human (FIH) clinical trial with its lead candidate Ent001.

Key Points: 
  • Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions, today announces the start of a Phase 1 first-in-human (FIH) clinical trial with its lead candidate Ent001.
  • Ent001 is designed to bind to TMEM219 and prevent cell death and the inflammation underlying these disease states.
  • “The initiation of this trial is a major development milestone for Ent001 and transitions Enthera into a clinical stage company.
  • The Phase 1 trial will evaluate Ent001 in up to 30 healthy adult volunteers in a randomised, double-blind, placebo-controlled single ascending dose (SAD) study in the Netherlands.

Rare Disease Week 2023: Exploring Accessibility in Rare Disease Clinical Research, 4-Day Webinar Series Hosted by Xtalks

Retrieved on: 
Tuesday, March 7, 2023
Horizon Therapeutics, FSR, Health care, ICON PLC, Veronica, Partner (business rank), CHES, In-product communication, MD, MBA, Sarcoidosis, Senior, Janssen Pharmaceuticals, Disease, Enrollment, Decentralized Trials & Research Alliance, Bristol Myers Squibb, Entrepreneurship, College, Research, AVP Research Foundation, MPH, Rutgers University, Commercialization, Chairperson, IBD, Doctor of Philosophy, DCTS, Host, Patient advocacy, Gallaudet University, DAWN, Real Time Information Group, ICON, DEI, Bachelor of Science, Public affairs, Zwanzig projection operator, Nursing, Pharmaceutical industry, Birth control, Management, Honours degree, The Swift Home Service Club, Neuromuscular junction

TORONTO, March 7, 2023 /PRNewswire-PRWeb/ -- Each panel in this 4-day webinar series, whether watched individually or in totality with the other panels, will provide insights into the value of accessibility in rare disease clinical research and how sponsors, patient advocates, researchers and regulators might move from discussion to action.

Key Points: 
  • In this free webinar series, learn about myriad types of accessibility considerations for rare disease clinical research.
  • Attendees will learn how accessibility considerations fit into diversity, equity, and inclusion (DEI) plans.
  • The featured speakers will discuss best practices in accessible clinical trial design and implementation.
  • Panel 1: Is Disability Part of Your DEI Planning and Engagement in Rare Disease?